Guo‐Bo Li

Virtual screening in small molecule discovery for epigenetic targets.

Yu Cao, Jun Zou, R. Xiang, 2015, Methods.

Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.

Shan Feng, P. Ji, Ze-Rong Wang, 2012, European journal of medicinal chemistry.

Discovery of novel mGluR1 antagonists: a multistep virtual screening approach based on an SVM model and a pharmacophore hypothesis significantly increases the hit rate and enrichment factor.

Jian-Ping Zhou, Shan Feng, Lin-Li Li, 2011, Bioorganic & medicinal chemistry letters.

Sensitive fluorogenic substrates for sirtuin deacylase inhibitor discovery.

Guo‐Bo Li, Ling-Ling Yang, Shan Liu, 2020, European journal of medicinal chemistry.

Interactions between sirtuins and fluorogenic small-molecule substrates offer insights into inhibitor design

Kai Chen, Guo‐Bo Li, Shan Liu, 2017 .

X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.

L. Zhong, Guo‐Bo Li, Ling-Ling Yang, 2018, European journal of medicinal chemistry.

Studies on the binding of rhaponticin with human serum albumin by molecular spectroscopy, modeling and equilibrium dialysis.

Guo‐Bo Li, Xiaoyun Hu, Jun Fan, 2012, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors.

Shaomeng Wang, Zhe-Sheng Chen, Guo‐Bo Li, 2021, Journal of medicinal chemistry.